BFRI
- Biofrontera Inc.
()
Overview
Company Summary
Biofrontera Inc. is a biopharmaceutical company that specializes in developing and commercializing dermatological drugs and medical devices for the treatment of skin conditions and diseases. The company's primary focus is on the development of therapies for non-melanoma skin cancers, specifically actinic keratosis (AK) and basal cell carcinoma (BCC).
Biofrontera utilizes innovative technologies to develop and improve treatment options for patients suffering from these skin conditions. The company's flagship product is Ameluz, a topical prescription drug used in photodynamic therapy (PDT) for the treatment of mild to moderate AK. Ameluz is combined with a specialized light source to selectively destroy diseased skin cells while preserving healthy tissue. Biofrontera also provides related medical devices and accessories required for PDT treatment.
In addition to Ameluz, Biofrontera has been developing a proprietary drug called BF-RhodoLED, which is also used in PDT procedures. This development can potentially enhance the efficiency and effectiveness of PDT treatment, providing an alternative option for patients.
Furthermore, Biofrontera is actively involved in research and development efforts to explore new treatment possibilities for various dermatological conditions. The company collaborates with leading academic institutions, research organizations, and medical professionals to further advance its product portfolio and bring new therapeutic options to market.
Biofrontera has a global presence, with operations in Europe and the United States. The company is focused on obtaining regulatory approvals and marketing its products in key markets worldwide, aiming to improve the lives of patients suffering from skin disorders while creating value for its shareholders.